Loss of CD62L on T Cells is Associated with Risk of Developing Progressive Multifocal Leukoencephalopathy in Patients Treated with Natalizumab
Researchers suggest that monitoring for the loss of CD62L expression on CD4+ T cells is a biomarker for risk assessment in patients treated with natalizumab who may develop PML, since other treatments do not show this pattern of C62L loss of expression.
CSF Neurofilament Light Chain Levels Correlate with Degree of Nerve Damage and Are Decreased in Patients with Relapsing Multiple Sclerosis Treated with Fingolimod
Late-breaking study results reported at ECTRIMS 2013 indicate that neurofilament levels may be reliable biomarkers of nerve damage and disease progression in patients with relapsing multiple sclerosis.
Riluzole Shows No Efficacy as a Neuroprotective Agent in Patients with Early-Stage Relapsing Remitting Multiple Sclerosis
Study results show that treatment with riluzole did not slow the rate of brain atrophy and did not demonstrate a detectable neuroprotective effect in patients with early RRMS.
THC:CBD Spray Improves MS-Associated Spasticity and Maintains Improvements throughout Long-term Treatment
Patients treated with oromucosal nabiximols spray experienced up to 30% reduction in spasticity, as measured by a numerical rating scale, after 12 months of treatment.
Dosing Frequency a Prime Factor in Non Adherence to Disease-modifying Therapy in Patients with Multiple Sclerosis
Nonadherence is highest in patients undergoing treatment with subcutaneous or intramuscular injection formulations of DMT.
iPad App Offers Promising New Way to Evaluate and Monitor MS Symptoms
Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.
Gains in Disease-related Disability Seen with Alemtuzumab in Patients with Multiple Sclerosis
Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.
Possible Indicator for Walking Speed Changes Identified in Subjects with Multiple Sclerosis
Study results show that hip flexion weakness and, to a lesser extent, ankle dorsiflexion weakness have the greatest impact upon changes in walking speed as MS progresses
Orally Administered Immunomodulator Continues to Show Promise as Treatment Option for Patients with Relapsing Remitting Multiple Sclerosis
Data indicate patients with relapsing remitting multiple sclerosis (RRMS) treated with BG-12 (dimethyl fumarate) showed no clinical disease activity for up to two years.
2 Commerce Drive Cranbury, NJ 08512